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Geographical disparities in access to cancer management and treatment services in 
England 
 
Abstract 
 
This study seeks to examine the extent to which cancer services are geographically located 
according to cancer incidence, and assess the association with cancer survival. We identified 
hospital sites serving English PCTs (Primary Care Trusts) with the management and treatment of 
breast, lung and colorectal cancer. Geographical access was estimated as travel time in minutes 
from LSOAs (Lower Super Output Areas) to the nearest hospital site and aggregated to PCT level. 
Correlations between PCT level mean travel times and cancer cases were estimated using 
Spearman’s rank correlation. Associations between PCT level mean travel times and cancer relative 
survival rates were estimated using linear regression with adjustment for area deprivation and for a 
PCT level measure of the reported ease of obtaining a doctor’s appointment. We found that cancer 
services tended to be located farther from areas with more cancer cases, and longer average travel 
times are associated with worse survival after adjustment for age, sex, year and area deprivation. 
This suggests that geographical access to cancer services remains a concern in England. 
 
 
Introduction 
 
Equity in access to healthcare is an important policy objective in England. The NHS was founded on 
the principle that services would be available to everyone and would be free at the point of delivery 
(NHS, 2015). Equity is also embedded in the operating model for the commissioning of specialised 
services, where NHS England seeks to provide consistent services to all regardless of location 
(NHS England, 2012). The provision of equitable cancer services is dependent on how they are 
organised. In England, service configuration since the 1990s has been based on the Calman and 
Hine report that recommended high quality and also accessible cancer care (Calman and Hine, 
1995). The report stated that, ‘All patients should have access to a uniformly high quality of care as 
close to the patient's home as possible’ and that ‘services should be planned to minimise travelling 
times whilst maintaining the highest standards of specialist care’ (Calman and Hine, 1995, p.6). 
These recommendations have been endorsed by consecutive Governments with particular attention 
paid to improving quality by establishing specialised cancer centres (Department of Health, 2000; 
Haward, 2006). Indeed, some improvements in cancer survival in England have been attributed to 
this increase in specialisation (Haward, 2006; Oliphant et al., 2013).  
 
The Calman-Hine recommendations also introduced a dilemma with regards to centralisation of 
services that ensures all patients have access to specialist care without having to travel too far for it  
(Munro, 2001). Healthcare providers and policymakers are thus faced with the substantial challenge 
of delivering geographically equitable cancer services within the constraints of finite healthcare 
resources and in the face of rising cancer incidence rates. Some geographical inequalities in access 
are inevitable (Gatrell and Wood, 2012) because certain populations, such as rural residents, will 
always need to travel farther to access specialist services. Inequalities in access are however 
unacceptable when they lead to avoidable disadvantages in health, and when they disproportionally 
affect those most in need (Gatrell and Wood, 2012). 
 
Access issues are felt more acutely by those with the greatest need for healthcare, such as patients 
with chronic conditions who require regular hospital visits, those with lowest mobility such as elderly 
or disabled patients and also the most deprived (Mungall, 2005; Bentham and Haynes, 1985). Poor 
access is also known to amplify the effect of deprivation, whereby patients with the longest travel 
times and also in the most deprived areas are least likely to have a histological cancer diagnosis 
and optimal treatment (Crawford et al., 2009). In the UK, studies using individual level data have 
shown a negative association between travel to hospital and uptake for cancer treatment (Jones et 
al., 2008; Lau et al., 2013) and increased odds of diagnosis at death (Jones et al., 2010). Longer 
distance to specialist cancer centres has also been associated with higher cancer stage at diagnosis 
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(Campbell et al., 2001) and with poorer survival (Campbell et al., 2000). These findings have been 
replicated outside the UK; in France, road distance to the nearest cancer centre was associated with 
worse survival (Dejardin et al., 2008). Studies that have employed alternative measures of 
healthcare accessibility have reached similar conclusions. For instance, one North American study 
used a derivative of the gravity model to capture the availability (supply) as well as the 
attractiveness (demand) of services (Wang, 2006), the study demonstrated an association between 
poor geographical access and advanced cancer stage (Wang et al., 2008).  
 
Our study builds on the existing evidence by investigating geographical inequities in access at a 
population level. We define geographical access as travel times in minutes from area of residence to 
the nearest hospital for cancer management or treatment. We have applied the definition of equity 
that is most generally accepted by policy makers; equal access for equal need (Oliver and 
Mossialos, 2004; Allin et al., 2007), with ‘need’ being the capacity to benefit where there is an 
effective and acceptable intervention to improve or prevent ill health (Matthew G, 1971; Wright et al., 
1998). Healthcare need at a population level can be measured by the ‘level of ill health’ (Allin et al., 
2007) and epidemiological measures such as prevalence or incidence can be used to describe ‘how 
much of it there is’ and ‘where it is located’ (Acheson, 1978; Williams and Wright, 1998).  
 
Geographical inequities in access will be determined where areas with higher need also have poorer 
access to cancer services. Additionally, geographical access will be associated with relative survival 
rates to determine whether areas with poor access also have the worst outcomes. Lung, breast and 
colorectal cancers are among the commonest cancers totalling to about 40% of all cancer incidence 
in the England and amounting to approximately 120,000 cases annually (Cancer Research UK, 
2016a). Treatment for these requires access to MDT, chemotherapy and radiotherapy, and so they 
are appropriate cancer sites for this work.  
 
 
 
Methods and Materials 
 
The study has a cross sectional ecological design, with measurements and inferences made at the 
level of NHS Primary Care Trust (PCT) area, as this was the scale at which data was available. It 
was not possible to obtain data on lower geographies for this study.  
 
We used multiple sources to obtain information on the location of cancer hospital sites. In England, 
this information is collected by the National Peer Review Team (National Peer Review Programme, 
2013) which holds details on the location of hospital sites that provide cancer treatment 
(chemotherapy and radiotherapy), and sites providing cancer management via multidisciplinary 
teams (MDTs). In order to account for the fact that patients in some parts of England may receive 
treatment in Wales and Scotland, we obtained similar Welsh data from the Welsh Health Directory 
(NHS Wales Informatics Services). At the time of the analysis, the Welsh Health Directory had 
complete information on the North Wales Cancer Network, but information was incomplete on the 
South Wales Cancer Network. Missing information was supplemented by Freedom of Information 
(FOI) requests from the Welsh Health Boards that are part of the South Wales Cancer Network. We 
also received data from the Information Services Division Scotland (Information Services Division, 
2015) on hospital sites located in the southern Scotland Health Boards that may serve some English 
patients; Dumfries and Galloway, Borders, Ayrshire and Arran, Lanarkshire, Lothian and Greater 
Glasgow and Clyde. The Scottish data did not have information on MDT presence, and therefore 
hospitals offering chemotherapy were used as a proxy for presence of a MDT.  
 
All the identified hospital sites were assigned a unique postcode, this is a geographical reference 
point in the U.K used to identify postal delivery areas (Office of National Statistics, 2015a). There are 
about 1.8 million postcodes and each have approximately 15 to 100 single addresses. Larger 
addresses that receive numerous mail items per day such as hospital sites, are assigned a single 
postcode and hence are accurately located (Office of National Statistics, 2015a).  
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Geographical access was determined as estimated travel time in minutes from all LSOA population 
weighted centroids in England, to the nearest hospital site offering treatment or management for the 
specified cancer. LSOAs are small geographic areas in England and Wales that are designed to 
improve the reporting of small area statistics. There are 32,844 LSOAs in England each with a 
population range of 1,000 to 3,000 residents (Office of National Statistics, 2015b). A population 
weighted centroid is a summary reference point at the centre of the population in a geographical unit 
(Office of National Statistics, 2013b). We used a Geographical Information System (GIS) (ArcGIS 
10.3, Esri Inc.) Network Analyst module to estimate travel times from all 2011 LSOA population 
centroids in mainland England, to all postcodes of the identified hospital sites. The travel times 
generated at LSOA level were thereafter aggregated to the PCT level as this is the level at which 
cancer data was available. Aggregation was achieved by summing up all LSOA level travel times in 
a given PCT and obtaining an average. PCTs were English health administrations at the time of data 
collection that were responsible for planning and purchasing primary, community and secondary 
health services. They have a median resident population of 203,000 (Office of National Statistics, 
2013c). There were 152 PCTs in England, at the time of this analysis.  
 
The National Radiotherapy Advisory Group (NRAG) recommend travel of no longer than 45 minutes 
for radiotherapy treatment (National Radiotherapy Advisory Group, 2007) and therefore we used this 
as an important threshold for radiotherapy treatment. For travel to MDT and Chemotherapy, we 
used 20 minutes to mark an important threshold as this was the approximate average travel time to 
hospitals in England during the study period (Department for Transport, 2014). Further, we 
quantified the proportion of the population in England whose travel may exceed these thresholds 
using ONS 2009 mid-year population estimates (Office of National Statistics, 2013c; Office of 
National Statistics, 2013a). 
 
The measure of population need adopted for this analysis was the number of cases of (breast (ICD-
10 C50), colorectal (ICD-10 C17-21 and C26) and lung (ICD-10 C33-34) cancer in a PCT. This was 
obtained as a three year average for 2008 - 2010 from the publicly available National Cancer 
Intelligence Network (NCIN) dataset of newly diagnosed cancer cases per year (National Cancer 
Intelligence Network, 2010). Primary outcomes were identified as one and five year PCT relative 
survival rates for each cancer, also obtained from the NCIN public dataset (National Cancer 
Intelligence Network, 2014a). These relative survival rates were estimated nationally by NCIN using 
the actuarial method that divides observed with expected survival rates to give a population level 
relative survival rate (Parkin and Hakulinen, 1991; National Cancer Intelligence Network, 2014b). 
The ‘observed one year survival rates’ were estimated as the number of persons diagnosed with the 
specified cancer between 2010 and 2012 with mortality follow up to the end of 2013. The ‘observed 
five year survival rates’ were also estimated in the same way but for patients who had a diagnosis 
between 2002 and 2004 and followed up to 2009. The ‘expected survival rates’ were based on the 
population life tables matched by age, sex and period of observation (Parkin and Hakulinen, 1991; 
National Cancer Intelligence Network, 2014b).  
 
Every effort was made to match the timescale covered by the estimated travel times with that of the 
incidence and survival data. This was achieved for travel to radiotherapy as there were fewer sites 
involved. Thus, travel time to radiotherapy was restricted to sites in operation before 2010 to match 
the incidence data. The three new radiotherapy hospital sites that opened after 2010 were excluded 
from the analysis; Bracknell Clinic, Fazackerley site of Clatterbridge Cancer Centre and The Christie 
at Royal Salford. For the regression analysis, we also used hospital sites identified as above 
because the cancer cases used to estimate relative survival rates would have been diagnosed in  
the same decade as the incidence data; 2010 - 2012 for 1 year survival and 2002 - 2004 for 5 year 
survival. We were however unable to discern MDT and chemotherapy sites by year of operation and 
therefore utilised the most recent data at the time of the analysis (November 2014). The 
discrepancies between the time of data collection and study period might have a slight effect on the 
results, but we think this effect is not substantial because English hospital sites would not have 
changed substantially during this decade. 
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Deprivation and ease of obtaining a general practitioner (GP) appointment were identified as 
potential confounders as they are independently associated with cancer survival. PCT level 
deprivation data was obtained from the English Index of Multiple Deprivation (IMD) (Department for 
Communities and Local Government, 2010). Good access to primary care is important in the early 
diagnosis and later prognosis of cancer and has previously been associated with lower rates of 
emergency admissions to secondary care (Cowling et al., 2013). Ease of obtaining a GP 
appointment was measured as the percentage of patients in a GP practice who were able to get an 
appointment to see or speak to a health professional during their most recent appointment, without 
the need to call back closer to or on the day they wanted an appointment. This is information is 
collected on an annual basis by the national GP Patient Survey of 2.75 million adults registered with 
a GP in England (NHS England, 2012-2013).  
 
Statistical analysis was conducted on using Stata (Version 13.1; StataCorp, College 
Station, TX, USA). Spearman’s rank correlation was used to correlate the unadjusted PCT cancer 
cases (need) with the estimated mean PCT travel times (access). Linear regression was used to 
examine the association between cancer relative survival rates and PCT level mean travel times, 
adjusting for age, sex, year, area deprivation and ease of GP access. Models were tested to ensure 
they met the following assumptions of the linear regression models; linearity, normality and 
homoscedasticity of the residuals. Sensitivity analysis was performed by modelling travel times both 
as a continuous measure and a grouped measure and examining any changes in the results. 
Standard errors of the relative survival rates were estimated to help determine the extent to which 
they were influenced by sampling variation (Ederer et al., 1961). A p-value (<= 0.05) was used to 
identify statistical significance in all analyses.  
 
 
Results 
 
Table 1 shows the distribution of the estimated mean PCT travel times. Radiotherapy was provided 
at the fewest number of hospital sites and therefore incurred the longest journey times with a mean 
of 23.7 minutes. Table 2 groups the PCTs in England by the mean travel times to radiotherapy 
hospital sites. It also gives the average deprivation score and estimated population in the different 
travel time groups. Using the mid-2009 PCT population, an estimated 3 million (5.72%) people and 
over 6,000 breast, colorectal and lung cancer patients in England lived more than 45 minutes from a 
radiotherapy facility during the study period. Figure 1 demonstrates how these mean travel times to 
radiotherapy are distributed in England at (a) LSOA and (b) PCT levels. For the purpose of brevity, 
only the travel to radiotherapy sites are provided. 
 
The number of cancer cases in a PCT across the three cancer types were positively and 
significantly correlated with longer PCT mean travel times to all hospital sites (p<0.01) (Table 3).  
 
 
Table 1 – Number of cancer services and estimated PCT mean travel times in England, Wales and 
Scotland* 
 
Type of service Number of 
sites 
Travel times in minutes PCT 
  Lowest Mean Highest 25th Quartile Median 75th Quartile 
Breast MDT 214 4.0 13.5 35.2 9.5 12.4 17.1 
Colorectal MDT 226 3.8 13.3 35.2 9.1 12.2 16.3 
Lung MDT 219 3.8 13.5 35.2 8.9 12.4 16.4 
Chemotherapy 231 3.6 13.1 35.2 8.7 11.9 15.7 
Radiotherapy 61 4.0 23.7 61.0 13.8 22.4 32.0 
 *Scottish data was obtained from the southern Health Boards only; Dumfries and Galloway, Borders, Ayrshire and Arran,   
   Lanarkshire, Lothian and Greater Glasgow and Clyde. MDT, multidisciplinary team. LSOA, Lower Super Output Area 
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Table 2 – Population estimates and cancer cases grouped by travel times to radiotherapy services. 
Cancer cases are estimated using PCT mid-2009 population estimates and three year annual cancer 
cases (2008 – 2010) 
 
Travel times to 
radiotherapy 
services (minutes) 
PCTs by 
Travel time 
categories 
PCT Overall IMD 
average by Travel 
time categories 
PCT Population mid 
2009 estimates 
(% of total) 
Estimated breast, 
colorectal and lung 
cancer cases 
0 – 14.99 43 28.11 11,451,308 (22.00%) 23,647 
15 – 29.99 65 22.26 24,010,852 (46.12%) 49,574 
30 – 44.99 34 21.24 13,616,842 (26.16%) 28,119 
45 plus 8 21.36 2,979,018 (5.72%) 6,148 
 
 
 
Table 3 – Correlation coefficient of mean PCT mean travel time to cancer services and PCT cancer 
incidence (number of new cases, annual average for 2008-2010) 
 
Number of new 
cases per year 
Breast 
MDT 
Colorectal 
MDT 
Lung 
MDT 
Chemotherapy Radiotherapy 
 
Breast  0.68**   0.68** 0.45** 
Colorectal   0.72**  0.72** 0.46** 
Lung    0.58** 0.58** 0.41** 
** p<0.01, * p<0.05. MDT, multidisciplinary team 
 
 
 
Figure 1 – Map of mean travel times to radiotherapy services estimated at (a) LSOA and (b) PCT levels. 
Travel times were calculated from all English LSOA centroids to all radiotherapy hospital sites 
operating within the study period. The computed travel times were later on aggregated to PCT level.  
 
 
The test for linearity using the Stata ‘nlcheck’ tool (Jann, 2008) showed that continuous ‘travel time’ 
and ‘ease of GP access’ variables failed to meet this assumption, which supported the decision to 
model these variables as categories. The ‘Shapiro-Wilk’ test for the normality of residuals also 
showed that some models failed to meet this assumption. However, this does not invalidate the 
analysis because the inferences in linear regression are robust to violations of normality so long as 
the sample size is reasonably large (Agresti, 2015; Xin and Su, 2009). Although it is recognised that 
non-normality does not affect the validity of the models, heteroscedasticity may affect it (Lumley et 
al., 2002). Four out of eighteen of the fully adjusted models did not meet this homoscedasticity 
assumption, these four models are for lung cancer access to MDT and Chemotherapy services 
(Supplementary tables 5 and 6), and hence these findings should be treated with caution. Modelling 
travel times as a continuous rather than categorical measure, did not alter the conclusions. 
Estimated standard errors of the relative survival rates across the three cancer sites, and for both 
one and five years were generally small compared to their associated estimates, and ranged from 
0.004 to 0.049.  
 
When estimated PCT mean travel times were regressed on cancer relative survival rates, the 
unadjusted models for breast and colorectal cancers showed that longer travel time was positively 
associated with longer survival. This was mostly evident for travel to MDTs and chemotherapy 
services and was statistically significant for five year relative survival rates. For example, for travel to 
breast and colorectal MDTs, PCTs with the longest mean travel had a significantly higher five year 
survival rates (breast coefficient = 1.79; SE = 0.79; t (148) = 2.26; p<0.05) and (colorectal coefficient 
= 4.10; SE = 1.16; t (148) = 3.54; p<0.01). Longer travel to radiotherapy was also positively 
associated with breast and colorectal cancer although this only reached statistical significance for 
the five year breast cancer survival rates (1.27; SE = 0.59; t (148) = 2.15; p<0.05) (Table 4). In 
contrast, the lung cancer analysis showed that PCTs with the longest mean travel had significantly 
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lower one and five year relative survival rates. The rest of the results for MDT and Chemotherapy 
analysis are presented as on-line supplementary material (Tables 5 and 6) for brevity. 
 
Adjusting for deprivation and ease of GP access revealed a clear survival gradient whereby PCTs 
with longer mean travel times consistently had poorer relative survival rates. This survival gradient 
was observed in travel to all services across the three cancers. As an example, Table 4 shows the 
regression output for the models of survival and access to radiotherapy treatment. The coefficients 
are percentage point differences in relative survival associated with each explanatory variable. The 
lung cancer output for example shows that an increase in travel times from the reference category 
‘less than fifteen minutes’ to the highest category ’45 plus minutes’, is associated with a predicted 
reduction in one year survival by -3.43 percent, p<0.05 (before adjusting), -4.02 percent, p<0.01 
(after adjusting for deprivation only) and -4.60 percent, p<0.01 (after adjusting for deprivation and 
ease of obtaining a GP appointment).  
 
In the lung cancer analysis, the travel – survival association was generally greater for one year than 
five year relative survival rates. For example, the lung cancer output in Table 4 shows the 
corresponding predicted reduction in the five year relative survival is -2.40 percent, p<0.05 (before 
adjusting), -2.72 percent, p<0.05 (after adjusting for deprivation only) and -2.98 percent, p<0.01 after 
adjusting for deprivation and ease of obtaining a GP appointment. Lastly, we found that the travel to 
radiotherapy - survival association was greater in colorectal and lung cancer compared to breast 
cancer (Table 4).   
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Table 4 – PCT mean travel times to the nearest radiotherapy site, associated with 1 and 5 year breast, colorectal and lung cancer relative survival rate. The 
table shows linear regression model outputs using 150 PCTs in England, adjusted for deprivation and ease of obtaining a GP appointment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Numbers show the regression coefficients (standardized β). All relative survival rates are adjusted for age, sex and year. ** p<0.01, *p<0.05.                                                                                                            
 
Not adjusted for deprivation 
or  ease of GP appointment Adjusted for deprivation 
Adjusted  deprivation &  ease of 
GP appointment 
 Breast CRC Lung Breast CRC Lung Breast CRC Lung 
Explanatory variables 
Outcome: 1 Year Relative Survival 
Travel times to Radiotherapy 
<15 minutes (reference) 
15 – 29.9 minutes 
30 – 44.9 minutes 
45 minutes plus 
 
 
-0.12 
0.24 
0.33 
 
 
-0.15 
-0.16 
-0.97 
 
 
-1.58* 
-3.08** 
-3.43* 
 
 
-0.59** 
-0.30 
-0.20 
 
 
-1.12* 
-1.29* 
-2.09* 
 
 
-2.09** 
-3.68** 
-4.02** 
 
 
-0.62** 
-0.30 
0.07 
 
 
-0.98 
-1.31* 
-2.67* 
 
 
-1.94* 
-3.71** 
-4.60** 
Deprivation (IMD)    -0.08** -0.17** -0.09* -0.09** -0.14** -0.07 
Ease of obtaining a GP appointment 
Quartile 1 - Difficult 
Quartile 2 
Quartile 3 
Quartile 4 - Easy       
-0.27 
-0.50* 
-0.81** 
 
-0.23 
0.05 
1.27 
 
-0.30 
-0.31 
1.14 
Intercept (Y) 96.44** 76.51** 34.39** 98.67** 81.15** 36.85** 99.42** 80.31** 36.24** 
R-squared 0.02 0.01 0.10 0.28 0.21 0.13 0.33 0.24 0.15 
Outcome: 5 Year Relative Survival 
Travel times to Radiotherapy 
<15 minutes (reference) 
15 – 29.9 minutes 
30 – 44.9 minutes 
45 minutes plus 
 
1.27* 
0.77 
1.07 
 
 
0.50 
-0.05 
-0.16 
 
 
-1.15* 
-1.32* 
-2.40** 
 
0.13 
-0.56 
-0.24 
 
 
-1.14 
-1.97* 
-2.05 
 
-1.44** 
-1.68** 
-2.72** 
 
0.20 
-0.55 
-0.72 
 
-0.84 
-2.03* 
-3.49* 
 
 
-1.34** 
-1.69** 
-2.98** 
Deprivation (IMD)    -0.19** -0.28** -0.05* -0.17** -0.22** -0.05 
Ease of obtaining a GP appointment 
Quartile 1 - Difficult 
Quartile 2 
Quartile 3 
Quartile 4 - Easy       
0.10 
0.84 
1.34* 
-0.04 
0.36 
3.28** 
 
-0.34 
-0.64 
0.40 
Intercept (Y) 84.54** 53.62** 9.614** 89.99** 61.50** 11.03** 88.75** 59.20** 11.05** 
R-squared 0.03 0.00 0.07 0.29 0.24 0.10 0.32 0.31 0.13 
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Discussion 
 
Our findings show that PCTs with more cases of breast, colorectal and lung cancer also have longer 
estimated mean travel times to the cancer management and treatment services we mapped. PCTs 
with longer mean travel times also have poorer relative survival rates after adjustment for area 
deprivation. These findings highlight the importance of examining inequalities in access to services 
and should inform NHS England’s mandate of ensuring equitable commissioning of specialised 
services (NHS England, 2012). 
 
We used an area level dataset for this analysis. It is likely that inference at this level will suffer to 
some extent from ecological fallacy by suggesting that relationships between areas may be related 
to individuals within them. Nevertheless, area based studies have several advantages, such as 
contributing to theory and hypothesis generation for future testing (Pearce, 2000). We have used 
publicly available datasets to highlight issues in access that warrant further investigation using more 
robust individual level datasets. The study also offers a national perspective on geographical access 
and augments the evidence previously conducted using smaller regions. Although incidence data is 
available at lower geographies, confidentiality restrictions meant we were unable to obtain this for 
the study. Relative survival rates on the other hand have not been computed at lower geographies in 
England, because the small number of cases and deaths at lower geographies introduces difficulties 
in standardising by age and sex. Whilst acknowledging that using relatively large PCT geographies 
conceals variation present at lower geographies, our findings are still informative because 
commissioning of cancer services in England took place at this scale (Okello et al., 2011). 
 
Using area level data we were able to demonstrate that areas with the poorest access also have the 
highest cancer cases (Table 3). This may be an indication that services in England may not be 
located according to population need. One explanation is that cancer services are more likely to be 
located in cities. This is contrary to the fact that the demand for these services is greater in less 
urban areas that carry a larger cancer burden due to larger percentage of older people. A 
programme commissioned by the National Cancer Action Team to model radiotherapy demand in 
England showed local area variation. Inner London PCTs with younger populations had a lower 
projected demand by the year 2020; 6,007 fractions per million in comparison to 20,827 fractions per 
million for more rural PCTs such as Devon (Round et al., 2013). This variation is due to 
geographical variation in age distribution because older age carries an increased cancer burden 
(Round et al., 2013). 
 
Associating PCT level mean travel times with cancer survival rates showed that areas with longer 
travel times to MDT and treatment have the worst cancer survival rates. Our unadjusted models for 
breast and colorectal cancers showed that areas with longer travel were more likely to have better 
relative survival rates. However, when we removed the confounding effect of deprivation we found 
the opposite; areas with longer travel were more likely to have poorer relative survival rates. This is 
because deprived populations are more likely to live in urban areas where most hospitals are 
located.  
 
Our findings indicate that travel time – survival association was strongest in lung and colorectal 
cancers than in breast cancer, this is particularly so for radiotherapy treatment (Table 4). Increasing 
distance from a cancer centre has been significantly associated with poorer survival in lung cancer 
(Campbell et al., 2000). Poor survival for those with poorer access may be explained by the 
increased likelihood of more advanced disease stage at diagnosis (Campbell et al., 2001), but why 
this might vary by tumour site is less clear. Other research suggests treatment uptake also appears 
to vary by tumour type; breast, rectal and lung cancers patients are all less likely to receive 
radiotherapy if they live farther from a radiotherapy site (Jones et al., 2008). Additionally, poor 
access to chemotherapy for rectal and lung cancer treatment (Jones et al., 2008) and poor access 
to surgical treatment for lung cancer has been associated with reduced likelihood for these 
treatments (Jones et al., 2008; Lau et al., 2013; Khakwani et al., 2013). There is also some evidence 
that geographical inequalities in cancer survival has declined for breast cancer but has persisted for 
other cancers (Walters et al., 2011), our findings may to some extent support this conclusion. 
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We also found that geographical access to radiotherapy had a stronger association with relative 
survival rates than geographical access to MDT and chemotherapy services. This is most likely 
because there are fewer sites for radiotherapy than for MDT and chemotherapy. NRAG 
recommends a threshold of 45 minutes travel for radiotherapy treatment (National Radiotherapy 
Advisory Group, 2007). Using ONS mid 2009 PCT population estimates and mean PCT travel times, 
we estimated that nearly 6% (3 Million) of the population in England lives farther than the 
recommended 45 minutes. It is likely that this population estimate is greater, this is because analysis 
at large areas such as PCTs conceals the extent of variation observed at smaller areas. For 
example, similar analysis at LSOA level showed that an estimated 10% (5 million) of the population 
in England lives over 45 minutes from a radiotherapy hospital site.  
 
Surgical operation is the main treatment for colorectal cancer and non-small cell lung cancer 
(Cancer Research UK, 2016b). In recent decades, the role of radiotherapy in cancer treatment was 
understated and this resulted to an under-investment of radiotherapy services in the UK (Cancer 
Research UK, 2009). However,  its curative effectiveness is now increasingly being recognised, with 
nearly 40% of cured cancer cases being attributed to radiotherapy treatment (National Radiotherapy 
Advisory Group, 2007). Where used curatively in lung cancer, it is generally reserved in the 
treatment of inoperable tumours often in elderly patients or those with other multiple morbidities 
(Louie et al., 2015). It is also used often to treat rectal but not colon cancers, whilst in breast cancer, 
radiotherapy is used after breast reconstruction and mastectomy (Cancer Research UK, 2016b). A 
substantial under-provision of radiotherapy services in England has been reported with an estimated 
63% gap between current activity levels and optimal treatment levels, however, improvements to 
increase provision are underway (National Radiotherapy Advisory Group, 2007). Our findings 
suggest that good access to radiotherapy treatment may be an important prognostic factor in breast, 
colorectal and lung cancer.  
 
This study has a number of limitations. It is a cross-sectional study and therefore causality cannot be 
determined; it is plausible for example that longer travel times might have caused poorer survival 
because of later diagnosis or inadequate treatment, although no data was available to let us test 
this. Another limitation is that we used number of cancer cases to indicate population need. It could 
be argued that the number of cases are only an indicator of the quantity of services needed, and not 
of the needs of individuals who have cancer. We have used aggregated PCT level data as individual 
level data or data from smaller geographies was not available at the time of the analysis. 
Aggregated data exposes the study to the ecological fallacy meaning the findings at a population 
level may not be inferred at individual level. Additionally, some of our data sources did not cover the 
same time period. For example there was no information to identify the location of MDT and 
chemotherapy hospital sites operating in the period over which the outcomes were measured, 
although it is unlikely that the geographical provision of services will have changed substantially over 
the period of this study.  Data were not available on mobile chemotherapy units or GP surgeries 
offering chemotherapy services and so we were unable to include them in our access measures. 
Another limitation is that PCTs are now obsolete geographies and have been replaced by CCGs 
(Clinical Commissioning Groups). At the time of analysis it was not possible to obtain cancer specific 
five year relative survival rates at CCG level.  
 
In conclusion, we have shown that despite equity in access being a key objective in the provision of 
healthcare, it remains an elusive goal in the provision of cancer services in England. Our findings 
suggest that longer travel times to services might lead to inadequate treatment and therefore poorer 
survival. We have also identified some research questions that warrant more in-depth future 
research. Firstly, colorectal and lung survival appear to be more sensitive to poor geographical 
access to radiotherapy than breast cancer (Table 4). Secondly, we found that in lung cancer, 
geographical access issues were more strongly associated with one year over five year survival 
rates. Thirdly, lung cancer survival appears to be more sensitive to geographical access to 
chemotherapy and MDT than both colorectal and breast cancer. 
 
Part of the challenge in meeting the equity goal may lie in the lack of a universal definition and 
monitoring criteria for equity in access (Allin et al., 2007). Another challenge lies in the trade-off that 
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results when attempting to meet contrasting goals such as equity and efficiency, with resources that 
are increasingly scarce. This has been recognised by the recent Cancer Research Taskforce for 
England that is working to develop a five year cancer survival improvement strategy on behalf of 
NHS England and other national health agencies (Independent Cancer Taskforce, 2015). The 
Taskforce has identified a need to revisit the issue of access to services in order to enable 
improvements in earlier diagnosis and quality of care. It has also recognised the inequitable 
commissioning and delivery of care, and has urged the tackling of variation to be a priority over the 
next five years. To achieve this, two recommendations that are relevant to this study have been put 
forward; an evaluation of evidence to determine whether service configuration of surgery merits 
further centralisation and, an evaluation of the impact on cancer outcomes of patients living 
distances from a cancer centre (Independent Cancer Taskforce, 2015).  
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